Call 413.540.1234 to
schedule an appointment
CONCERN/EAP: 413.534.2625
Billing questions? Call: 413.540.1212
CRISIS: 413.733.6661

Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Patients Prefer Doctors Who Engage in Face-to-Face VisitsU.S. Better Able to Tackle Health Emergencies: ReportFirst Opioid Lawsuit Targeting Pharmacy Benefit ManagersMost Doctors' Offices Don't Offer Flexibility for UninsuredSafety Info for Opioids Found LackingNonoptimized Drug Therapy Costs More Than $500 Billion AnnuallyFDA Cracks Down on Caffeine-Loaded SupplementsCigarette Tax Hike Could Ease Poverty for Millions Worldwide: StudyCDC: Aggressive Action Needed to Contain Antibiotic ResistanceCould Medical Pot Help Curb the Opioid Abuse Crisis?Medical E-Records Not Without Risks: StudyHealth Groups Sue FDA to Speed Review of E-CigarettesEHR Usability Contributes to Possible Patient Harm EventsAHA: Solving the Dilemma of Not Enough HeartsUnchecked Air Pollution a Death Sentence for Millions: StudyPersonal Health Info Found in Recycling at Five HospitalsTask Force Issues Stronger Skin Cancer Prevention GuidelinesFDA Considers Lowering Nicotine Levels in CigarettesDoctors Facing Challenge to Help Needy While Protecting PracticesPharmacists Encouraged to Learn More About Herbal SupplementsBan Menthols to Help Some Smokers QuitStem Cell Clinics Pitch Pricey, Bogus 'Cures' for Knee PainMany Americans Think Docs Order Too Many Tests, MedsIs Herbal Drug Kratom a Health Friend or Foe?Early Studies Often Show Exaggerated Treatment EffectStrong Tobacco Laws May Weed Out Vapers, TooUnderstanding Rx Nonadherence Can Improve AdherenceBystander Use of Defib Device Doubles Chances of Surviving Cardiac ArrestNew Research Debunks Two Medical Marijuana MythsTake Early Clinical Trials With a Grain of SaltCould Hackers Target Heart Devices?Protecting Your Electronic Health RecordsAfter Another Shooting Tragedy, 'Stop the Bleed' Kits Urged for SchoolsPatients Want Physicians to Have Greater ConnectivityYour Tax Dollars Fund Research on Hundreds of New MedsFour Best Practices Outlined to Prevent Health Care CyberattacksMany Patients Know Too Little About Their MRI, CT Scans: StudyUnsafe Water Found in Faucets Across the U.S.Health Tip: Prevent Exposure to LeadHealth Tip: Online Pharmacies You Should AvoidDon't Count on an American to Do CPRPoll: Personal Beliefs Shouldn't Allow Doctors to Refuse to TreatFDA Says U.S. Will Now Produce Critical MRI ComponentPicking a New Primary Care DoctorUber, Lyft Rides May Not Help Boost Doc Visits for Poorer Patients2018 Immunization Schedule Issued for U.S. ChildrenA Hidden Source of 'Superbugs' in Hospitals?2018 Immunization Schedule Issued for U.S. AdultsTop Three Challenges Identified for Pharmacists in 2018Responding to Opioid Crisis, FDA Puts More Restrictions on Imodium
Questions and AnswersLinksBook Reviews
Related Topics

Responding to Opioid Crisis, FDA Puts More Restrictions on Imodium

HealthDay News
by -- E.J. Mundell
Updated: Jan 30th 2018

new article illustration

TUESDAY, Jan. 30, 2018 (HealthDay News) -- Increasingly, people addicted to opioid painkillers are using dangerously high doses of the diarrhea drug Imodium (loperamide), either to get high or to help ease withdrawal.

So, on Tuesday the U.S. Food and Drug Administration said it's putting new restrictions on the packaging of the medication, dubbed by some as "the poor man's methadone."

"When higher than recommended doses are taken we've received reports of serious heart problems and deaths with loperamide, particularly among people who are intentionally misusing or abusing high doses," FDA commissioner Dr. Scott Gottlieb said in an agency news release.

Because opioid abusers are using the drug in greater numbers, the FDA is requesting that makers "change the way they label and package these drugs, to stem abuse and misuse," Gottlieb said.

The FDA already slapped a warning on OTC loperamide labeling in the spring of 2017, cautioning users about the dangers of misuse.

The latest changes relate to the drugs' packaging.

Specifically, packaging of Imodium should now only "contain a limited amount of loperamide appropriate for use for short-term ['Traveler's'] diarrhea according to the product label," Gottlieb said.

For example, that might mean a package would only contain eight 2-milligram capsules of the diarrhea drug in a blister pack, the FDA said.

The new rules will also seek to eliminate the sale of loperamide in large bottles -- sales that typically occur via the Internet, Gottlieb said.

"The abuse of loperamide requires the purchase of extremely large quantities," he noted, and "today's action is intended to change how the product is packaged, to eliminate these large volume containers. We know that many of the bulk purchases of these large volumes are being made online through major online web retailers."

One busy emergency room doctor said he's witnessed the problem firsthand, and "applauds" the FDA's latest move.

"I most often encounter patients who abuse loperamide either to get high or to self-treat symptoms of opioid withdrawal," said Dr. Robert Glatter, of Lenox Hill Hospital in New York City. "Many people view it as low risk since they think it's only medicine to treat diarrhea."

"But those who abuse it to get high are gambling with their life, in essence," he said. "Simply put, escalating use may place you at risk for an overdose. An overdose of loperamide can make you stop breathing, drop your blood pressure, or even cause a fatal heart arrhythmia."

But Glatter said even more can be done to curb this new danger.

"It also starts with education, and informing parents and teens via social media platforms of the dangers of loperamide abuse," he said.

More information

There's more on the opioid abuse epidemic at the U.S. National Institute on Drug Abuse.